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Abstract
Aims: Efficient oxidative protein folding (OPF) in the endoplasmic reticulum (ER) is a key requirement of the
eukaryotic secretory pathway. In particular, protein folding linked to the formation of disulfide bonds, an
activity dependent on the enzyme protein disulfide isomerase (PDI), is crucial. For the de novo formation of
disulfide bonds, reduced PDI must be reoxidized by an ER-located oxidase (ERO1). Despite some knowledge of
this pathway, the kinetic parameters with which these components act and the importance of specific param-
eters, such as PDI reoxidation by Ero1, for the overall performance of OPF in vivo remain poorly understood.
Results: We established an in vitro system using purified yeast (Saccharomyces cerevisiae) PDI (Pdi1p) and ERO1
(Ero1p) to investigate OPF. This necessitated the development of a novel reduction/oxidation processing strategy to
generate homogenously oxidized recombinant yeast Ero1p. This newmethodology enabled the quantitative assessment
of the interaction of Pdi1p and Ero1p in vitro bymeasuring oxygen consumption and reoxidation of reduced RNase A.
The resulting quantitative data were then used to generate a simple model that can describe the oxidizing capacity of
Pdi1p and Ero1p in vitro and predict the in vivo effect of modulation of the levels of these proteins.
Innovation:We describe a model that can be used to explore the OPF pathway and its control in a quantitative way.
Conclusion: Our study informs and provides new insights into how OPF works at a molecular level and
provides a platform for the design of more efficient heterologous protein expression systems in yeast. Antioxid.
Redox Signal. 00, 000–000.
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Introduction
The oxidative protein folding (OPF) pathway of theendoplasmic reticulum (ER) has been well characterized in
the yeast Saccharomyces cerevisiae, both in terms of identifi-
cation of components and defining how they interact. The key
components of the pathway are protein disulfide isomerase in
yeast (Pdi1p) (13) and ER oxidase in yeast (Ero1p) (16, 41),
encoded by the essential PDI1 and ERO1 genes, respectively.
Biochemical, structural, and genetic characterization of
the pathway have demonstrated that it comprises a linear
electron transfer pathway. Electrons from the thiol (SH)
groups of reduced proteins flow via Pdi1p to Ero1p through a
series of thiol:disulfide oxidoreductions, to a bound flavin
adenine dinucleotide (FAD) group within Ero1p, and thence
to molecular oxygen (O2). The net result of this process is the
formation of disulfide (S-S) bonded proteins and hydrogen
peroxide (18, 19, 55, 56).
Given the similarities in the core components of the yeast
and human OPF systems, it is not surprising that some
functional complementation of components between the
species has been observed both in vivo (38) and in vitro (4).
Despite this, there are marked differences between species in
the number of members of the protein disulfide isomerase
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(PDI) and endoplasmic reticulum oxidase (ERO) families, in
their regulation and in the associated components of the
pathway.
Yeast and human ERO proteins show functional identity but
also significant structural differences, especially in the number
and arrangement of nonactive-site disulfide bonds (18, 25).
These disulfides play regulatory roles that differ considerably
between the species, although both in yeast and in human
systems, the formation and breakage of regulatory disulfides in
ERO are critically catalyzed by PDI (1–3, 5, 7, 8, 28, 43).
Recently it has been proposed that the mode of regulation of
OPF differs between humans and yeast in that the human
pathway provides for clear on/off switching, whereas regula-
tion in the yeast system is more graduated (37, 66).
In S. cerevisiae, a simple linear pathway operates and both
ERO1 and PDI1 are essential genes. However, viability of the
pdi1 deletion strain can be restored by overexpression of a
number of alternative PDI-like genes such as EUG1 (52). In
contrast, human cells lacking both ERO genes (a and b) are
viable, in part, because other proteins are available in the ER
that can function as electron acceptors from PDI. These in-
clude the peroxidases GPX7 and GPX8 and possibly the
peroxiredoxin PrxIV, which can use hydrogen peroxide
(H2O2) generated by ERO or other systems, as terminal
electron acceptor (26, 36, 42, 53, 59, 67). Such activities are
lacking in the yeast ER. Furthermore, the human pathway is
also more complex in that a large number of PDI family
members can interact with ERO in either a regulatory or
catalytic electron transfer role (34, 50).
To better understand the OPF pathway and its regulation,
PDI-dependent electron transfer has been effectively recon-
stituted in vitro using purified proteins where pathway activity
can be assayed by monitoring formation of disulfide-bonded
proteins (30, 54) or consumption of O2 (27, 57, 58) (Fig. 1).
Disulfide-bonded proteins including antibodies, cytokines,
and serum proteins are valuable biopharmaceuticals, and S.
cerevisiae remains an attractive, safe, and low-cost host cell
in which to generate them (47, 65).
Many of these high-value biopharmaceuticals contain in-
ter- and/or intramolecular disulfide bonds and thus need to
transit through the ER to be correctly folded. However, the
secretory capacity of S. cerevisiae is low and has to deal with
many fewer secreted proteins than a mammalian cell, for
example. As a result, there have been attempts to engineer
OPF to increase the production of such high-value disulfide-
bonded targets. Indeed, overexpression of yeast and human
PDI in yeast was shown at an early stage to improve the
production of a range of recombinant disulfide-bonded pro-
teins (44, 47), and this strategy is exploited industrially in the
production of human serum albumin and transferrin, for ex-
ample (14, 40).
While showing a degree of success in terms of improving
product yield and/or authenticity, interventions intended to
increase the yield of the pathway in production and secre-
tion of recombinant proteins can have unexpected outcomes
[see e.g., de Ruijter et al. (45)]. A key issue is that knowl-
edge of kinetic properties of the components and quantita-
tive analyses of the pathway are lacking and this deficit has
discouraged systems biology approaches to rational engi-
neering of the OPF pathway (57). In this study, we have
reconstituted the OPF of S. cerevisiae in vitro and obtained
the first quantitative data on the kinetics of the overall
system and developed a model capable of predicting how
the system can be modified to enhance OPF. Such infor-
mation will underpin future design strategies for enhanced
secretion of high-value complex biopharmaceuticals from
this simple eukaryote.
Results
Production of active recombinant Pdi1p and Ero1p
To date, biochemical studies using Pdi1p have relied on
bacterially produced protein, which is biochemically active
(29, 30, 37, 57). In native environments, a 21-residue N-
terminal signal sequence directs Pdi1p to the ER where it is
then cleaved to give the mature and functional protein. To
FIG. 1. Methods for in vitro analysis of electron flow in
the yeast OPF pathway. The ER oxidative folding pathway
can be reconstituted with Ero1p and Pdi1p in the presence of
dissolved O2 as the terminal electron acceptor and either GSH
(Assay 1) or reduced protein substrate (Assay 2) as the electron
source. The operation of the pathway can be monitored either
by the disappearance of O2 (Assay 1), by the change in redox
state of the substrate protein (Assay 2). ER, endoplasmic re-
ticulum; Ero1p, purified yeast endoplasmic reticulum oxidase
1; GSH, glutathione; GSSG, glutathione disulfide; H2O2, hy-
drogen peroxide; O2, molecular oxygen; OPF, oxidative pro-
tein folding; Pdi1p, purified yeast protein disulfide isomerase.
Innovation
Oxidative protein folding (OPF) in eukaryotes utilizes
two proteins, protein disulfide isomerase (PDI) and en-
doplasmic reticulum oxidase (ERO), to generate correctly
positioned disulfide bonds. Using an advanced in vitro
refolding process to isolate functional recombinant yeast
ERO (Ero1p), we carried out the first quantitative as-
sessment of the rates of PDI/ERO oxidation by oxygen.
Based on these quantitative data, we developed an ordi-
nary differential equations-based model of the oxidizing
capabilities of the yeast endoplasmic reticulum in vivo.
This model gives new insights into native yeast OPF and
suggests that engineering strategies to enhance the se-
cretion of authentic high-value recombinant proteins from
yeast need to consider an expanded parameter space
comprising both Pdi1p and Ero1p, depending on the ef-
ficiency with which Pdi1p and the recombinant substrate
interact.
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mimic functional Pdi1p and increase protein yield in bacterial
expression systems, it is common to remove the signal se-
quence from the construct and replace it with a polyhistidine
tag (30, 54, 57). We used this strategy to obtain highly pure
Pdi1p22-530, lacking the signal sequence but containing an
N-terminal six-histidine tag (Fig. 2A).
In contrast to Pdi1p, Ero1p does not express well as a full-
length construct and consequently, previous studies have
relied on truncated Ero1p constructs (10, 18). We chose to
use the longest Ero1p construct we could express in reason-
able yield in Escherichia coli without mutation of cysteine
residues (Ero1p19-424), again with an N-terminal six-histidine
tag to facilitate purification.
The resulting purified Ero1p19-424 existed as a mixture of
oxidation products postpurification. To yield homogeneously
oxidized Ero1p19-424 containing stoichiometric amounts of
FAD, we exploited a controlled sequence of reduction and
oxidation in the presence of FAD (Fig. 2B). Using an assay
for O2 consumption in a 1,4-dithiothreitol (DTT)-dependent
manner (Fig. 2C), we were able to demonstrate that the
Ero1p19-424 reproducibly consumed O2 with general kinetic
characteristics as reported by others (37, 57) (Fig. 2D). Our
homogeneously oxidized Ero1p19-424 had a maximum rate of
0.8 lM O2 per lM Ero1p per second when treated with
10mM DTT.
Rate of thiol oxidation is linearly dependent
on Pdi1p and Ero1p concentrations
Glutathione (GSH)-mediated O2 consumption (Fig. 1,
Assay 1) was used to study the limits of the coupled system
using variable Ero1p and Pdi1p concentrations. At a fixed
1 lM concentration of Ero1p, the rate of O2 consumption was
dependent on the concentration of Pdi1p (Fig. 3A, B). This
dependence was linear at concentrations <15 lM before the
system saturated (Fig. 3C). Conversely, at a fixed 5 lM
concentration of Pdi1p, the maximum rate was linearly de-
pendent on Ero1p at concentrations up to 2 lM (Fig. 3D). In
both cases, the maximum rate of O2 consumption observed in
saturating conditions was*1.5 lM/s.
Although GSH is present within the ER, the physiological
substrates of Pdi1p are proteins. A frequently used model
substrate in vitro is reduced and denatured ribonuclease A
(rdRNase A) (30, 54), a single chain protein containing four
intrachain disulfide bonds. In the GSH-dependent assay of the
Pdi1p/Ero1p interaction, the electron donor, GSH, is present
in vast excess. When GSH is replaced as an electron source
by rdRNase A, the number of electrons available to the sys-
tem is limited by the solubility of rdRNase A.
Using the rdRNase A assay (Fig. 1, Assay 2), we found that
at 60lM rdRNase A (i.e., 240lM disulfides) and 1 lM
FIG. 2. Purification of proteins for analysis of the yeast OPF pathway. (A) Reducing SDS-PAGE of Pdi1p purification
(I) input, lanes 1–9; fractions from HiTrap Q FF purification. (B) Reducing SDS-PAGE of Ero1p purification after AMS
trapping: Lane 1, post-Ni-NTA purification; lane 2, reduction of the Ni-NTA eluent by DTT (30mM); lanes 3–6, reox-
idation in the presence of FAD at 10min, 30min, 60min, and 18 h; lane 7, purified Ero1p trapped with AMS; lane 8,
purified Ero1p trapped with NEM. (C) Schematic showing the Ero1p activity assay where Ero1p reduced by DTT is
reoxidized by O2, which is measurable using a Clarke electrode. (D) O2 consumption assay using a Clarke electrode. One
micromolar Ero1p equilibrated for 100 s before addition of DTT (10mM final concentration) to initiate Ero1p-mediated O2
consumption (primary axis). The graph displays two replicates of the experiment ( and ), respectively. The nonlinearity
of O2 consumption is shown by the increase in rate of reaction overtime to a maximum before decreasing again to 0
(secondary axis). AMS, 4-acetamido-4¢-maleimidylstilbene-2,2¢-disulfonic acid; DTT, 1,4-dithiothreitol; FAD, flavin ad-
enine dinucleotide; Ni-NTA, Ni2+ loaded nitrilotriacetic acid modified sepharose; SDS-PAGE, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis.
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Ero1p, the maximum rate of O2 consumption was again lin-
early dependent on the concentration of Pdi1p, reaching
saturation >10 lM (Fig. 4A, B). Similarly, at 5 lM Pdi1p, the
rate was dependent on Ero1p concentrations (Fig. 4B). O2
consumption correlated with a change in redox state of the
ribonuclease A (RNase A) (Fig. 4C and Supplementary
Fig. S1), and the observed formation of disulfide bonds in the
protein was clearly dependent on the presence of both Pdi1p
and Ero1p (Fig. 4D). It is noteworthy that at a sub-
strate:Pdi1p:Ero1p ratio of 60:5:1, the substrate can be fully
reoxidized within 20min in this assay.
The pH dependence of the Pdi1p/Ero1p catalytic cycle
To determine the optimum pH of the GSH-promoted Pdi1p
and Ero1p catalytic cycle, the interaction of 5 lM Pdi1p and
1 lM Ero1p was assessed at different pH values (Fig. 5A, B).
This analysis showed an extreme dependence on the pH of
the reaction mixture for the GSH-driven system with a nar-
row window of optimum activity focused around pH 8. In
contrast to this narrow activity range observed with GSH as
the electron source, the system driven by 60lM RNase A
showed broader tolerance to fluctuations in pH (Fig. 5B). We
were unable to find reported values for the pH of the yeast
ER, although for mammalian cells this has been reported as
7.5 (33, 39). Thus, under these pH conditions, proteins would
be the preferred substrate for Pdi1p despite the presence of
GSH.
The relationship between Pdi1p oxidation state
and refolding activity
To examine in more detail how the internal oxidation state
of Pdi1p relates to oxidative refolding activity in our in vitro
system, a polyethylene glycol (PEG)-trapping assay was
exploited that, through alkylation of reduced cysteines, leads
to defined shifts in apparent molecular weight (48). Analysis
of PEG-treated Pdi1p over the course of the oxidative re-
folding reaction byWestern blotting showed that within 100 s
of RNase A refolding, the initially fully oxidized Pdi1p be-
comes heavily reduced with a prominent species appearing
at a size expected for four reduced cysteines, as well as a less
abundant species corresponding to six reduced cysteines, that
is, fully reduced Pdi1p (Fig. 6A, B; Supplementary Figs. S2
and S3).
Niu et al. (37) predicted that a fully reduced species of
Pdi1p should form under strongly reducing conditions, which
is the case for our in vitro system (Fig. 6A, B; Supplementary
Figs. S2 and S3). This suggests that our assays operate in the
high Ero1p activity regime proposed by Niu et al. (37).
However, contrary to these data, we observed that the max-
imal activity of 5 lM Pdi1p and 1 lM Ero1p occurred be-
tween 400 and 600 s, when these more reduced components
would have been depleted from the mixture (Fig. 6A and
Supplementary Fig. S2). The presence of these more reduced
forms of Pdi1p at the very beginning of the reaction rather
than during the more active period of activity implies that
FIG. 3. The oxidizing activity of the yeast OPF pathway is dependent on the concentration of Pdi1p and Ero1p. (A)
The O2 consumed when variable concentrations of Pdi1p are reoxidized by Ero1p (1lM) in the presence of 40mM GSH.
Buffer composition: 100mM Tris-AcOH, 50mM NaCl, pH 8, 25C. All reagents except the Ero1p were combined and
equilibrated, with constant stirring, to give a static baseline before Ero1p addition 100 s after the initiation of the experi-
ment. An average of at least two replicates is plotted. (B) The nonlinearity of the observed O2 consumption was assessed by
determining the change in rate of O2 consumption over the course of the experiment, using 10 s intervals. Three repre-
sentative curves are shown (20, 5, and 1 lM), all exhibiting a slow increase in rate toward a maximum value before
decreasing. (C, D) The extracted maximum rates of O2 consumption for all repeats, as determined from the data in (B), and
plotted against enzyme concentration for Pdi1p (C) and Ero1p (D). AcOH, acetic acid; NaCl, sodium chloride.
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reduction is a side effect of Ero1p activation rather than
controlling the rate of Pdi1p activity.
Our data also showed that different ratios of Pdi1p to
Ero1p consume O2 and, therefore, reoxidize RNase A at
different rates (Fig. 4A, B). Comparison of the redox poise of
the Pdi1p, the distribution of oxidation states, over the course
of these reactions (Fig. 6A, B; Supplementary Figs. S2 and
S3), showed that at 5:1 Pdi1p:Ero1p ratio, Pdi1p returns to a
basal state of oxidation, consisting of fully oxidized Pdi1p but
with a significant proportion with 1 reduced disulfide, much
faster than an equimolar (1:1) ratio (Fig. 6C).
Modeling oxidative folding
Our biochemical assays interrogate OPF from several
different angles. We sought to unify the quantitative infor-
mation from these assays by using an ordinary differential
equations-based mathematical model of the biochemical re-
actions.
In establishing the model, we made several design deci-
sions. For example, previous studies have shown that Pdi1p
has asymmetric active sites with only one of the CGHC
motifs responsible for the oxidase activity and the other being
FIG. 4. The interaction of Pdi1p and Ero1p mediates reoxidation of rdRNase A. (A) O2 consumption observed when
60 lM rdRNase A was added to Pdi1p and Ero1p. The concentration of Pdi1p was varied between 1 and 20lM with a fixed
Ero1p concentration of 1 lM. All reagents except Ero1p were combined and stirred at a constant speed for 100 s before
addition of Ero1p. (B) The maximum rate of O2 consumption at different enzyme concentrations: variable Pdi1p with fixed
[Ero1p] (1 lM) (dark gray · ) and variable Ero1p with fixed [Pdi1p] (5 lM) (black filled circles). Data are shown for all
replicates. (C) 15% Tris-Gly SDS-PAGE analysis of the Pdi1p (5 lM)/Ero1p (1lM) mediated reoxidation of RNase A
overtime using AMS trapping. (D) O2 consumption for RNase A reoxidation. The primary axis, for 5lM Pdi1p and 1 lM
Ero1p (dark gray), no Pdi1p (dotted line), and no Ero1p (dashed line). The secondary axis shows the quantitation, by Image
J, of the oxidized fraction from (B) over the course of the experiment.:, no Pdi1p; · , no Ero1p;B, 5 lM Pdi1p and 1 lM
Ero1p. rdRNase A, reduced and denatured ribonuclease A; Tris-Gly, tris-glycine buffer.
FIG. 5. GSH-mediated Pdi1p/
Ero1p interaction is pH regu-
lated. (A) O2 consumption traces
for 5 lM Pdi1p and 1lM Ero1p
when treated with 40mM GSH
under identical conditions except
for variation of the reaction pH. (B)
Comparison of the maximum rate
of O2 consumption at different pH
values with either GSH ( · ) or
rdRNase A (C) as electron source.
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more important for isomerase activity (30). Consequently, to
simplify modeling, we only utilized one Pdi1p active site in
our model. Several reactions, such as the oxidation of Ero1p by
molecular O2, are in reality multistep reactions. However,
these are likely fast reactions, and as a consequence we
modeled these as a single-step reaction. The reduction of ox-
idized Pdi1p by GSH likely occurs by sequential reaction with
two consecutive GSH moieties, which are biochemically very
similar. Because of their similarity we assumed that these re-
actions occur with identical rates. However, as we show
hereunder, the rate constants for these reactions are not lim-
iting for the time evolution of the model, so this has no con-
sequences for deriving the remaining limiting rate constants.
In initial model runs, we also experimented with the in-
clusion of an inhibiting reaction between peroxide and Pdi1p,
but since this did not alter the behavior of the model, we did
not include this reaction in our final runs. We did, however,
include an initial activation step involving the sequential
reduction of two regulatory disulfides that yields active
Ero1p. This step was introduced to account for the clear
presence of a lag phase in our biochemical assays (Fig. 3A),
but also to reflect the published biochemical evidence for
such a step (37, 49).
We constructed the final model based on these con-
siderations (Fig. 7A) and implemented the model in the
biochemical simulation software, Complex Pathway Si-
mulator (COPASI) (21). After initiation of the model with
the known input concentrations of the molecular compo-
nents, we then sought to determine the reaction rates by
parameter fitting to our experimentally determined O2
consumption in the system.
We initially observed that the model found well-fitting
solutions with very different parameter combinations, indi-
cating that the model was strongly underdetermined. We,
therefore, experimentally determined rates for Ero1p oxida-
tion, by observing O2 consumption in reactions containing
only Ero1p and varying concentrations of DTT (Supple-
mentary Fig. S4).
In addition, we characterized the diffusion of environ-
mental O2 into the Clarke cell by depleting O2 with sodium
dithionite, and by determining rates of recovery of the O2
concentration in the open cell (Supplementary Fig. S5).
When we fixed the rates for these reactions using the ex-
perimentally determined values and repeated the parameter
fitting exercise, all rate constants except the Pdi1p:GSH in-
teraction were reproducibly determined within very narrow
ranges (Fig. 7B and Supplementary Fig. S6).When compared
with the experimental O2 consumption data (B), the pre-
dicted O2 consumption curves (· ) at different Pdi1p and
Ero1p concentrations showed excellent correlation (Fig. 7C),
with a nonlinear increase in maximum d[O2]/dt when the
Pdi1p concentration is increased >15:1 Pdi1p:Ero1p (Fig. 7D).
In vitro rates and their relationship
with OPF activity in vivo
The measuring of biochemical activity in vitro, and the
interpretation of this activity in silico, provides quantitative
information that can be used to explore characteristics of the
OPF pathway in vivo.
Intracellular levels of Pdi1p and Ero1p in yeast have been
reported as 28,000 and 5200 molecules per cell, respectively,
in recent high-quality proteome data sets (22). Given esti-
mated ER volumes of 0.2–0.4 lm3 (62), this would be
equivalent to concentrations of 155 and 29lM. To estimate
the substrate flux processed by these factors, we used recent
proteomics studies (15, 23, 51, 60, 63) to identify all proteins
residing in or passing through the ER (i.e., all proteins re-
ported to be present in the ER, Golgi, endosome, vacuole, cell
wall, or reported to be extracellular).
We combined these data with published protein turnover
rates (9) and with the number of cysteines per protein, to
FIG. 6. The bulk Pdi1p redox
state remains reduced when it
becomes the limiting component.
(A) Anti-Pdi1p Western blot show-
ing the redox state of Pdi1p over the
course of Ero1p-mediated RNase A
(60lM) reoxidation catalyzed by
5lM Pdi1p, 1lM Ero1p. (B) Anti-
Pdi1p Western blot showing the re-
dox state of Pdi1p over the course of
Ero1p-mediated RNase A (60lM)
reoxidation catalyzed by 1 lM
Pdi1p, 1lM Ero1p. (C) Densito-
metry analysis of the oxidized band
over the course of the experiment
for 5lM Pdi1p, 1lM Ero1p (B)
and 1lM Pdi1p, 1lM Ero1p (· ).
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arrive at an estimate of around 269,000 cystines formed per
minute. This assumes that every single cysteine pair present in
all proteins passing through the ER is converted to a cystine
through Pdi1p activity, which is unlikely to be the case. This
value is thus an upper limit only, and likely substantially
overestimates the need for catalyzed disulfide bond formation.
In our in vitro experiments, the maximal capacity of Pdi1p
for disulfide bond formation (i.e., when both Ero1p and GSH
are provided in excess) is*15 disulfide bonds per minute per
Pdi1p molecule (estimated from the data shown in Fig. 3D).
Thus, if sufficient Ero1p is present in vivo, the estimated
Pdi1p population in yeast could process up to 400,000 dis-
ulfide bonds per minute.
The in vivo Ero1:Pdi1 ratio of roughly 1 in 5 is slightly
below the ratio where Ero1p becomes saturating in vitro (2:5,
Fig. 3D), indicating that in vivo Pdi1p activity might be
limited by Ero1p availability. In contrast, Pdi1p can also act
as an isomerase in addition to forming disulfide bonds, in
reactions that are net neutral in terms of electron flow but that
nevertheless remove Pdi1p molecules from the active pool
while the isomerization reactions are being catalyzed. This
would reduce the effective Pdi1p concentration itself.
To analyze how well these estimates reflect the biology of
yeast cells, we tested experimentally how such cells cope
with an enforced reduction of their Pdi1p content, using
strains in which the original promoter was replaced by a Tet-
responsive tetO7promoter that is repressible by addition of
doxycycline to the growth medium (6).
We observed that substantial Pdi1p depletion can be tol-
erated with only a minor reduction in growth rates. At the
highest doxycycline concentration used in our experiment,
Pdi1p concentrations were reduced to 23% of the wild-type
content (Fig. 8A and Supplementary Fig. S7A), yet this still
permitted growth at 24% of the wild-type growth rate.
Moreover, the ratio of observable Pdi1p oxidation states was
not substantially affected by this depletion either (Fig. 8B or
Supplementary Fig. S7B).
In contrast to the monotonic decrease of both Pdi1 content
and growth rates with doxycycline concentration in a tetra-
cycline (Tet)-PDI1 strain, Ero1p levels showed a more
complex relationship between the corresponding parameters
(Fig. 8B and Supplementary Fig. S7C). In the absence of
doxycycline, the promoter replacement strain contained
higher levels of Ero1p than the control. Interestingly, how-
ever, this increased expression coincided with a reduction in
growth rates of 5%–10%. Upon addition of doxycycline at
increasing concentrations, Ero1p levels initially dropped but
then recovered slightly around the 0.4mg/L mark. Growth
rates moved parallel to the Ero1p content, initially dropping
before recovering and then dropping again (cf the inset panel
in Fig. 8B).
Interestingly, in our blot, the Ero1p band displayed as an
apparent double band, and the depletion of Ero1p in the
doxycycline-repressible strain coincided with a clear shift
from a predominantly lower molecular weight isoform to a
higher molecular weight isoform and low Ero1p levels. We
interpret this overall complex behavior as evidence for some
currently not understood regulation of Ero1p expression,
possibly involving post-translational modifications that may
be regulated by feedback loops (since it is dependent on in-
tracellular Ero1p levels).
Notably though, like the Tet-PDI1 strain, the Tet-ERO1
strain allows substantial growth to occur even when this
protein is depleted to <25% of wild-type levels. These
FIG. 7. Kinetic Modeling of
GSH-promoted Pdi1p/Ero1p in-
teraction. (A) Representation of
the model showing the reaction
steps incorporated to define the
electron transfer from GSH to mo-
lecular O2. (B) A comparison of 10
separate model repeats for each of
the terms defined in (A). R1 was
determined experimentally and
was, therefore, not incorporated in
the fitting. (C) The bulk experi-
mental O2 consumption data where
the solid lines are color coded to
show [Pdi1p] compared with the
O2 consumption data generated by
the best fitting data, dashed lines,
that is, the best fitting data were
those achieved using the parame-
ters from the 3rd of the 10th mod-
eling replicates shown in
Figure 6B. (D) Comparison of the
experimentally observed (B) max-
imum for d[O2]/dt with that calcu-
lated using the data predicted ( · )
by the model. Color images are
available online.
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observations corroborate our in silico prediction that the
oxidative capacity in S. cerevisiae in vivo comfortably ex-
ceeds the required capacity.
Discussion
S. cerevisiae is a well-exploited host system for the pro-
duction of secreted recombinant proteins due, in part, to its
potential to carry out post-translational modifications such as
inter- and intramolecular disulfide bond formation. However,
the secretory capacity of S. cerevisiae cells is far less than that
of cultured mammalian cells, presumably as a consequence
of a less developed OPF pathway that has not evolved to
handle the secretion of large amounts of secretory proteins.
Yet this yeast species has been successfully engineered to
yield commercially viable levels, but this has been done
empirically rather than in a directed and informed manner.
The latter requires a systematic understanding of the yeast
OPF pathway and its regulation using both in vivo and in vitro
approaches, with the latter being hampered by inefficient
methods for isolating key OPF components, in particular the
ER-located oxidase Ero1p (57).
In this study, we have developed an efficient reduction/
oxidation processing strategy to generate homogenously
oxidized yeast Ero1p expressed in E. coli strains. This new
methodology has for the first time enabled the in vitro
quantitative assessment of the interaction of Pdi1p and Ero1p
by measuring O2 consumption and glutathione disulfide
(GSSG) formation through nicotinamide adenine dinucleo-
tide phosphate (NADPH)-coupled assays. The resulting
quantitative data have allowed us to generate a simple model
that can describe the oxidizing capacity of Pdi1p and Ero1p
in vitro and predict the in vivo effect of modulation of the
levels of the key components of the OPF, thereby allowing us
to begin to explore yeast oxidative folding in a quantitative
way. Overall, our study informs and provides new insights
into how OPF works at a molecular level.
One fundamental difference between yeast and mamma-
lian PDI and endoplasmic reticulum oxidase 1 (ERO1) pro-
teins is that the yeast proteins are glycosylated in vivo,
whereas here we carry out in vitro studies exclusively with
nonglycosylated proteins produced in E. coli. The report that
the specific activities of the natural glycosylated yeast Pdi1p
versus a recombinant nonglycosylated form are similar (31)
FIG. 8. Yeast fitness correlates with intracellular levels of Pdi1p and Ero1p. This figure presents analyses of strains
where expression of the PDI1 or ERO1 genes was placed under control of a doxycycline-repressible promoter (Tet-Pdi1 and
Tet-Ero1, respectively), compared with isogenic control strains containing the natural promoters (R1158). (A) Top panel:
anti-Pdi1 Western blots of samples treated with 5k PEG maleimide that shifts reduced Pdi1p to higher molecular weight,
anti-Pdi1 Western blots of non-PEG maleimide-treated protein showing total Pdi1p content per cell, and loading controls for
the Pdi1p Western blots (a lower molecular weight nonspecific band cross-reacting with the anti-Pdi1p antibody). Bottom
panel: growth curves for selected strains and conditions, corresponding to symbols underneath the Western blots. (B) Top
panel: anti-Ero1 Western blot of non-PEG maleimide-treated samples, and loading control (Pgk1p). Bottom panel: growth
curves for selected strains and conditions, corresponding to symbols underneath the blots. The inset graph shows growth
rates of Tet-ERO1 strains, expressed relative to the growth rate of R1158, for a wider range of doxycycline concentrations.
PEG, polyethylene glycol; Tet, tetracycline.
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would suggest that the presence or absence of N-glycans has
little or no effect on the isomerase activity of this enzyme,
although detailed equivalent comparisons for Ero1p have not
to our knowledge been reported in the literature.
Overall, our study informs and provides new insights into
how OPF works at a molecular level. The yeast ER is more
strongly oxidizing than the cytoplasm, with a GSH:GSSG
ratio of 1:1 to 3:1 in the ER compared with 30:1 to 100:1 in
the cytoplasm (24), meaning that GSH concentrations may
reach 10mM based on measured total GSH concentrations in
the ER of HeLa cells (35). If GSH is readily available as an
electron source for the oxidative folding machinery, it is not
clear how proteins could compete for access to Pdi1p.
Our observations of the extreme pH dependence of Pdi1p
oxidation by GSH, but not by a protein substrate (Fig. 5),
suggest that this interference is not relevant at the reported pH
within the ER (12). The potential for continuous futile cycles
of GSH-mediated reduction and oxidation was proposed as a
significant issue (57) to the ‘‘active site asymmetry’’ model
of Pdi1p activity proposed by Kulp et al. (30). The obser-
vation of the strong pH dependence of such futile cycles,
therefore, adds weight to this model.
Interestingly, pH dependence has also been observed for
the human PDI/ERO interaction (4). Assessment of the oxi-
dation of rdRNase A in the absence of either Pdi1p or Ero1p,
at pH 8 where spontaneous oxidation would be faster than in
the ER where the pH is 7.5, shows that nonenzyme-mediated
substrate oxidation is far slower than that observed in the
catalyzed processes (Supplementary Fig. S8) and, therefore,
are not able to account for difference in activity between the
two electron sources.
Another observation that is consistent with the ‘‘active site
asymmetry’’ model, which posits that one active site is uti-
lized as an oxidase and the other as a reductase and an
isomerase, is our inability to observe completely oxidized
Pdi1p, either in vitro or in vivo. At the end of the in vitro
experiment, when reduced RNase A is consumed, the resting
state of the Pdi1p contains a significant proportion of Pdi1p
containing a single reduced disulfide (Fig. 6A, B and Sup-
plementary Figs. S2 and S3). Similarly, even when Pdi1p
levels are significantly reduced in vivo, the proportion of
reduced oxidized protein is not altered (Fig. 8A and Sup-
plementary Fig. S7B).
Comparison of the modeled system with the in vivo envi-
ronment of the yeast ER suggests that the total oxidation
capacity of a yeast cell is 400,000 disulfide bonds per minute,
not considering alternative roles of Pdi1p such as isomeri-
zation, which would diminish this capacity. In silico assess-
ment of the secretory pathway, which OPF is part of, suggests
a maximum requirement of 269,000 disulfides to be formed
per minute. This is likely a substantial over estimate of the
real required rate, since few proteins contain all their cyste-
ines within Pdi1p-catalyzed disulfide bonds. Depletion ex-
periments confirm the notion that Pdi1p is provided in
substantial excess over requirements of wild-type strains.
These observations appear at odds with the fact that Pdi1p
overexpression can enhance secretion of a variety of re-
combinant proteins (14, 47). Our quantitative model predicts
that 10-fold elevation in the steady-state levels of Pdi1p
should only increase the capacity of the OPF pathway by 1.4-
fold, whereas similar overexpression of Ero1p should more
than double the capacity of the pathway (Fig. 9). Thus, ma-
nipulating Ero1p levels might provide a more promising
strategy compared with manipulating Pdi1p levels.
A number of studies have indeed shown that Ero1p over-
expression can improve production of a range of recombinant
substrates, from single chain variable fragments (scFvs) to T
cell receptors, and for some substrates including different
scFvs, Ero1p overexpression was indeed more beneficial than
Pdi1p overexpression (61). Similarly, de Ruijter et al. (45)
showed that increasing levels of Ero1p consistently enhanced
titers of an antibody product expressed in yeast more than
was the case when Pdi1p levels were increased (45). How-
ever, these studies also demonstrate significant variability
and substrate specificity in the behavior of different recom-
binant products.
It is likely that target recombinant mammalian proteins
will have evolved in the significantly more complex envi-
ronment of the mammalian OPF pathway and may interact
suboptimally with yeast Pdi1p. This may explain why in
some cases, individual substrates respond well to Pdi1p
overexpression.
In conclusion, we have developed a novel method for the
processing of Ero1p that enables, for the first time, an un-
derstanding of the in vitro concentration dependencies of
the Pdi1p/Ero1p catalytic cycle. Based on a suite of bio-
chemical assays, we generated a detailed computational
model that accurately describes the interaction of Pdi1p and
Ero1p for the oxidation of substrates. This model gives new
insights into the yeast OPF and should form a platform on
which to design future engineering strategies to enhance the




The plasmid encoding a codon optimized version of
Ero1p19-424 was a kind gift from Lloyd Ruddock (Uni-
versity of Oulu). The plasmid expressing yeast Pdi1p22-530
without its N-terminal signal sequence was produced by
polymerase chain reaction amplification of the relevant PDI1
sequence from plasmid pUKC470 using a forward primer
(GCGATGCATCACCATCACCACCATATGCAACAAGA
GGCTGTGGCC) and a reverse primer (CGCGCGGGATCC
CGCTATTACAATTCATCGTGAATGGCATCTTCTTC)
FIG. 9. Predicted increase in oxidative folding capacity
on Pdi1p/Ero1p overexpression. The increase in oxidative
folding capacity of the Pdi1p/Ero1p system when the con-
centration of the OPF components is increased. C, 5 lM
Pdi1p and 1 lM Ero1p; · , increase in Ero1.
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followed by digestion using NsiI and BamHI (Promega,
Madison, Wisconsin) and ligation into a pET15b vector.
Protein production
Pdi1p- and Ero1p-encoding plasmids were transformed
into the BL21 [DE3] pLysS strain of E. coli (Invitrogen,
Carlsbad, CA) by heat shock at 42C for 60 s. Transformants
were selected by growth on LB (Lysogeny broth; 1% w/v
tryptone, 0.5% w/v yeast extract, 1% w/v NaCl) agar plates
containing 35 lg/mL chloramphenicol (Sigma Aldrich, St
Louis, MO) and 100lg/mL ampicillin (Sigma Aldrich). In-
dividual transformed colonies were used to inoculate 10mL
of LB containing 35lg/mL chloramphenicol and 100 lg/mL
ampicillin and then grown overnight at 37C.
The resulting cultures were centrifuged at 1359 · g, the
supernatant was removed, and the resulting cell pellet was
resuspended in 1mL of LB and then used to inoculate 1 L of
LB containing 35 lg/mL chloramphenicol and 100 lg/mL
ampicillin. The cultures were grown to an OD600 of 0.6 be-
fore gene expression was induced as follows. Pdi1p synthesis
was induced by 1mM isopropyl b-d-thiogalactopyranoside
(IPTG; Melford Laboratories, Ipswich, Suffolk) and incu-
bated for 4 h at 30C.
Ero1p synthesis was induced by addition of 1mM IPTG
and 10 lM FAD (Sigma Aldrich) followed by incubation at
20C for 12–16 h. The cells were harvested by centrifugation
at 1359 · g for 10min before resuspension in 20mM phos-
phate, 50mM sodium chloride (NaCl), pH 7.4, plus protease
inhibitor cocktail (Sigma Aldrich).
Protein purification: Ero1p
Cells producing Ero1p were disrupted by sonication and
the resulting lysate was treated with 2Mmagnesium chloride
(MgCl2, 10mM final concentration) and deoxyribonuclease
A (DNase A, 150U/L culture; Sigma Aldrich) and incubated
for 30min at room temperature.
The resulting lysate was clarified by centrifugation at
27,216 g for 30min at 4C. The supernatant was removed and
treated with 5 M NaCl and 1 M imidazole to give 0.5 M and
10mM concentrations, respectively, before incubation with
Ni2+ loaded nitrilotriacetic acid modified sepharose (Ni-
NTA) resin formed from chelating sepharose (2mL of resin
per 1 L of culture purified; GE Healthcare, Chicago, IL) for
1 h at room temperature. The resin was collected and washed
with 10mL of 20mM phosphate, 50mM NaCl, 10mM im-
idazole, pH 7.4, and then 10mL of 20mM phosphate, 50mM
NaCl, pH 7.4, before elution of bound proteins with 1mL
fractions of 20mM phosphate, 50mM NaCl, 50mM ethyle-
nediaminetetraacetic acid (EDTA), pH 7.4.
The resulting solution was diluted to 100lM protein
concentration before being treated with 30mM DTT (Mel-
ford Laboratories) and incubated at room temperature for 1 h.
Any precipitated material was removed by centrifugation at
20422 · g for 10min before DTT removal by buffer ex-
change with PD10 cartridges (GE Healthcare) equilibrated
with 20mM phosphate, 50mM NaCl, pH 7.4. The approxi-
mate protein concentration was determined by absorbance at
280 nm before a 10-fold molar excess of FAD (*750lM)
was added to the mixture and incubated for 12–16 h at room
temperature.
The mixture was concentrated using a 10 kDa molecular
weight cutoff (MWCO; Pall, NY) centrifugal filter before
loading onto a Superdex 200 16/600 gel column (GE
Healthcare) equilibrated with 20mM phosphate, 50mM
NaCl, pH 7.4. The appropriate fractions were collected,
protein concentration was determined in the presence of 0.1%
sodium dodecyl sulfate to determine protein:FAD ratio, ali-
quoted, and stored at -80C.
Protein purification: Pdi1p
The Pdi1p purification protocol was based on that de-
scribed by Lappi and Ruddock (32). In brief, cells producing
Pdi1p were lysed by incubation at room temperature in the
presence of 0.5% (v/v) Triton X-100 and a combination of
DNase A (150U/L culture) and MgCl2 (10mM) for 30min.
The resulting lysate was clarified by centrifugation at
20422 · g for 30min at 4C and then incubated with Ni-NTA
(1mL/L culture) for 2 h at room temperature. The resin was
then collected and washed with 10mL of 20mM phosphate,
50mM NaCl, 10mM imidazole, pH 7.4 and then 10mL of
20mM phosphate, and 50mM NaCl, pH 7.4. The bound
protein was eluted using 1mL fractions of 20mM phosphate,
50mM NaCl, and 50mM EDTA, pH 7.4, and then buffer
exchanged into 20mM phosphate and 50mM NaCl, pH 7.4,
using a PD10 column.
The resulting mixture was purified using a 5mL HiTrap Q
FF anion exchange column (GE Healthcare) with a nonlinear
gradient between 20mM phosphate, 50mM NaCl, pH 7.4
(buffer A), and 20mM phosphate, 1M NaCl, pH 7.4 (buffer
B) (postinjection 12mL buffer A, 2mL of 0%–20% buffer
B, 20mL of 20%–75% buffer B, 15mL of 75%–100%
buffer B, and 10mL of 100% buffer B). The appropriate
fractions were then combined and concentrated using a
10 kDa MWCO centrifugal filter before aliquoting at
freezing at -20C.
Preparation of rdRNase A
Bovine pancreatic RNase A (Sigma Aldrich) was dis-
solved in 20mM phosphate, 8 M urea, pH 8, to a concen-
tration of *750lM and then treated with DTT at a final
concentration of 30mM. The reaction mixture was incubated
for 4 h at room temperature before quenching the reaction by
lowering the pH to 3 with acetic acid (AcOH). The buffer was
then exchanged to 0.1 M AcOH using PD10 columns. The
protein concentration was determined and samples were
aliquoted before lyophilization to dryness.
O2 consumption assay
O2 consumption was measured using a Clarke O2 electrode
(DM10; Rank Brothers, Bottisham, Cambridge) in conjunc-
tion with a Pico Technologies Data Logger and PicoLog
software (Pico Technologies, St Neots, Cambridgeshire). A
1mL chamber was utilized and a final reaction volume of
600 lL was used for each experiment.
GSH-mediated O2 consumption assay
Stock solutions of GSH (Sigma Aldrich) were prepared
fresh before the start of every experiment and stored on ice.
The thiol concentration of these stock solutions was calcu-
lated using Ellman’s assay (11) and this concentration was
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used to determine the volume to be added to give 40mMGSH
in the electrochemical cell.
Purified Pdi1p was combined with 10 ·O2 consumption
buffer (1M tris-acetic acid buffer [Tris-HAc], 500mMNaCl,
pH 8), H2O, and GSH (40mM), and the baseline O2 level was
allowed to stabilize for 100 s before addition of Ero1p to the
electrochemical cell.
DTT-mediated O2 consumption assay
Purified Ero1p (1 lM) was combined with 10 ·O2 con-
sumption buffer and H2O and the baseline O2 level was al-
lowed to stabilize for 100 s before addition of 1 M DTT.
Analysis of RNase A oxidation by AMS trapping
Lyophilized rdRNase A was dissolved in 0.1 M AcOH to
765 lM. Purified Pdi1p, 10 ·O2 consumption buffer, H2O,
and RNase A (60 lM) (Sigma Aldrich) were combined and
the baseline O2 level was allowed to stabilize for 100 s before
addition of purified Ero1p (variable lM).
Over the duration of the experiment, 10 lL aliquots were
removed from the electrochemical cell and quenched by the
addition of 10mM of 4-acetamido-4¢-maleimidylstilbene-
2,2¢-disulfonic acid (AMS; Molecular Probes, Invitrogen,
Carlsbad, CA) to give a final concentration of 1mM.
The samples were incubated for 1 h before treatment with
4 · sodium dodecyl sulfate–polyacrylamide gel electropho-
resis (SDS-PAGE) loading dye +5% (v/v) 2-mercaptoethanol
(Sigma Aldrich) and then heated to 95C for 5min.
Three microliters of each sample was run on a 15% tris-
glycine buffer (Tris-Gly) SDS-PAGE at 180V and then
stained with Instant Blue (Expedeon, Over, Cambridge)
stain. The resulting gels were scanned using an Epson Per-
fection 3200 flatbed scanner and band analysis was carried
out using ImageJ software (46).
In vitro analysis of Pdi1p oxidation state
by PEG trapping
Six hundred microliters O2 consumption assays as already
described, with rdRNase A as an electron source and varying
Pdi1p and Ero1p concentrations, were analyzed. At different
time points, 10 lL samples were removed from the electrode
chamber and trapped by the addition of 1lL of 200mM 5k
PEG maleimide solution (Sigma Aldrich). The sample was
thoroughly mixed and incubated for at least 30min before the
addition of 4 · SDS-PAGE loading buffer incorporating 5%
(v/v) 2-mercaptoethanol. The samples were then boiled at
95C and analyzed using SDS-PAGE and Western blot.
Polyclonal antibodies were raised in a rabbit against purified
Pdi1p and were produced by Capra Science (A¨ngelholm,
Sweden).
In vivo analysis of Pdi1p oxidation state
by PEG trapping
To allow for regulation of the expression of the PDI1 gene,
the tet-O promoter was introduced into the yeast strain R1158
in place of the native PDI1 gene promoter. This strain en-
abled knockdown of PDI1 expression and was constructed
using the KanMX4-tetO cassette method developed by Yen
et al. (64). The resulting strain was named tet-pdi1.
Overnight cultures of R1158 and tet-pdi1 were re-
inoculated to an OD600 of 0.2 in fresh yeast extract peptone
dextrose (2% w/v glucose, 1% w/v yeast extract, and 2% w/v
bactopeptone) and grown for 6 h in the absence or pres-
ence of doxycycline (Sigma Aldrich) and added to a final
concentration of either 0.02 lg/mL (45 nM) or 0.1 lg/mL
(225 nM).
After 6 h, five OD600 units of cells were harvested at
16,100 g and proteins were extracted in cell lysis buffer
(1· phosphate-buffered saline, 100mM NaCl, 100mM
EDTA, pH 8.0, and 1 · protease inhibitor cocktail tablet) with
or without 20mM of 5k PEG maleimide using glass bead
lysis. Proteins were analyzed using reducing SDS-PAGE and
Western blot analysis. Polyclonal antibodies were raised in a
rabbit against purified Pdi1p and were produced by Capra
Science (A¨ngelholm, Sweden).
Computational modeling of O2 consumption
A structural biology markup language version of the model
file is available from the Biomodels database (17) under ac-
cession number MODEL1902080001. The fitting of experi-
mental data to reactions was achieved using the COPASI 4.18
parameter estimation module (21). The average O2 con-
sumption data were calculated for each Pdi1p and Ero1p
concentration variable with the 100 s of baseline stabilization
time removed. Each change in parameter was accompanied by
10 repeats of the fitting to determine reproducibility of the fits
in terms of the derived k value.
To compare between each run, the average root-mean-
squared-deviation (RMSD) for each experiment was calcu-
lated by averaging the values for each of the individual
protein concentration variables obtained in each run. The
rank order of fitting was defined by the lowest to highest
RMSD value.
Estimation of protein oxidation rates in yeast in vivo
The main data source to identify proteins passing through
the ER was Wiederhold et al. (63), who reviewed and sum-
marized information on mass spectrometry-based subcellular
localization experiments from 18 different pre-2010 studies.
A number of later studies (15, 23, 51, 60) were used to
complete this set.
Abundance data for each protein were used as reported in
Ho et al. (20), protein half-life data were from Christiano
et al. (9), and a doubling time was assumed as 120min.
Abundance, decay-rate, and number of cysteines per protein
are listed in Supplementary Table S1. The maximum number
of disulfide bonds to be formed per minute was calculated as
kCys¼+ni¼ 1Ai  º
Cysi
2




where Ai is the abundance of the ith protein and Cysi is the
number of cysteines it contains, ki its degradation rate, and td
the doubling time of the growing culture. The equation is
based on the standard math for first-order reactions, as-
suming that in the steady state, proteins need to be formed
with a rate that balances their decay and their dilution
through growth. It is assumed that only even number of
cysteines can be oxidized.
YEAST OXIDATIVE PROTEIN FOLDING PATHWAY 11
Acknowledgments
The study reported in this article was supported by a pro-
ject grant from the Biotechnology and Biological Sciences
Research Council (BBSRC, ref. no. BB/M009815/1). We
thank Richard Williamson (Kent) and Lloyd Ruddock (Oulu)
for advice and the provision of key reagents. We dedicate this
article to the memory of our dear friend and collaborator
Robert Freedman without whom none of the work reported
here would have been possible.
Authors’ Contributions
D.M.B., G.L.S., and E.L.B. performed the experiments;
D.M.B., E.L.B., R.B.F., T.v.d.H., and M.F.T. designed the
research, analyzed the data, and wrote the article.
Author Disclosure Statement












1. Appenzeller-Herzog C, Riemer J, Christensen B, Sørensen
ES, and Ellgaard L. A novel disulphide switch mechanism
in Ero1alpha balances ER oxidation in human cells. EMBO
J 27: 2977–2987, 2008.
2. Appenzeller-Herzog C, Riemer J, Zito E, Chin K-T, Ron D,
Spiess M, and Ellgaard L. Disulphide production by Ero1a-
PDI relay is rapid and effectively regulated. EMBO J 29:
3318–3329, 2010.
3. Araki K, Iemura S, Kamiya Y, Ron D, Kato K, Natsume T,
and Nagata K. Ero1-a and PDIs constitute a hierarchical
electron transfer network of endoplasmic reticulum oxido-
reductases. J Cell Biol 202: 861–874, 2013.
4. Araki K and Nagata K. Functional in vitro analysis of the
ERO1 protein and protein-disulfide isomerase pathway. J
Biol Chem 286: 32705–32712, 2011.
5. Baker KM, Chakravarthi S, Langton KP, Sheppard AM, Lu
H, and Bulleid NJ. Low reduction potential of Ero1alpha
regulatory disulphides ensures tight control of substrate
oxidation. EMBO J 27: 2988–2997, 2008.
6. Bellı´ G, Garı´ E, Aldea M, and Herrero E. Functional
analysis of yeast essential genes using a promoter-
substitution cassette and the tetracycline-regulatable dual
expression system. Yeast 14: 1127–1138, 1998.
7. Benham AM, van Lith M, Sitia R, and Braakman I. Ero1-
PDI interactions, the response to redox flux and the im-
plications for disulfide bond formation in the mammalian
endoplasmic reticulum. Philos Trans R Soc Lond B Biol Sci
368: 20110403, 2013.
8. Chambers JE, Tavender TJ, Oka OBV, Warwood S, Knight
D, and Bulleid NJ. The reduction potential of the active site
disulfides of human protein disulfide isomerase limits oxi-
dation of the enzyme by Ero1a. J Biol Chem 285: 29200–
29207, 2010.
9. Christiano R, Nagaraj N, Fro¨hlich F, and Walther TC.
Global proteome turnover analyses of the yeasts S. cere-
visiae and S. pombe. Cell Rep 9: 1959–1965, 2014.
10. Chu Y, Yang C, Chen X, Zheng W, Yang Y, and Tang Y.
Structure–function analysis of human protein Ero1-La.
Biochem Biophys Res Commun 389: 645–650, 2009.
11. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Bio-
phys 82: 70–77, 1959.
12. Elsutohy MM, Chauhan VM, Markus R, Kyyaly MA,
Tendler SJB, and Aylott JW. Real-time measurement of the
intracellular pH of yeast cells during glucose metabolism
using ratiometric fluorescent nanosensors. Nanoscale 9:
5904–5911, 2017.
13. Farquhar R, Honey N, Murant SJ, Bossier P, Schultz L,
Montgomery D, Ellis RW, Freedman RB, and Tuite MF.
Protein disulfide isomerase is essential for viability in
Saccharomyces cerevisiae. Gene 108: 81–89, 1991.
14. Finnis CJA, Payne T, Hay J, Dodsworth N, Wilkinson D,
Morton P, Saxton MJ, Tooth DJ, Evans RW, Goldenberg H,
Scheiber-Mojdehkar B, Ternes N, and Sleep D. High-level
production of animal-free recombinant transferrin from
Saccharomyces cerevisiae. Microb Cell Fact 9: 87, 2010.
15. Forsmark A, Rossi G, Wadskog I, Brennwald P, Warringer
J, and Adler L. Quantitative proteomics of yeast post-golgi
vesicles reveals a discriminating role for Sro7p in protein
secretion. Traffic 12: 740–753, 2011.
16. Frand AR and Kaiser CA. The ERO1 gene of yeast is re-
quired for oxidation of protein dithiols in the endoplasmic
reticulum. Mol Cell 1: 161–170, 1998.
17. Glont M, Nguyen TVN, Graesslin M, Ha¨lke R, Ali R,
Schramm J, Wimalaratne SM, Kothamachu VB, Rodriguez
N, Swat MJ, Eils J, Eils R, Laibe C, Malik-Sheriff RS,
Chelliah V, Le Nove`re N, and Hermjakob H. BioModels:
expanding horizons to include more modelling approaches
and formats. Nucleic Acids Res 46: D1248–D1253, 2018.
18. Gross E, Kastner DB, Kaiser CA, and Fass D. Structure of
Ero1p, source of disulfide bonds for oxidative protein
folding in the cell. Cell 117: 601–610, 2004.
19. Gross E, Sevier CS, Heldman N, Vitu E, Bentzur M, Kaiser
CA, Thorpe C, and Fass D. Generating disulfides enzy-
matically: reaction products and electron acceptors of the
endoplasmic reticulum thiol oxidase Ero1p. Proc Natl Acad
Sci U S A 103: 299–304, 2006.
20. Ho B, Baryshnikova A, and Brown GW. Unification of
protein abundance datasets yields a quantitative Sacchar-
omyces cerevisiae proteome. Cell Syst 6: 192–205, 2018.
21. Hoops S, Sahle S, Gauges R, Lee C, Pahle J, Simus N,
Singhal M, Xu L, Mendes P, and Kummer U. COPASI—a
COmplex PAthway SImulator. Bioinformatics 22: 3067–
3074, 2006.
22. Horton LE, James P, Craig EA, and Hensold JO. The yeast
hsp70 homologue Ssa is required for translation and in-
teracts with Sis1 and Pab1 on translating ribosomes. J Biol
Chem 276: 14426–14433, 2001.
23. Hsu P-H, Chiang P-C, Liu C-H, and Chang Y-W. Char-
acterization of cell wall proteins in Saccharomyces cere-
visiae clinical isolates elucidates Hsp150p in virulence.
PLoS One 10: e0135174, 2015.
24. Hwang C, Sinskey AJ, and Lodish HF. Oxidized redox state
of glutathione in the endoplasmic reticulum. Science 257:
1496–1502, 1992.
12 BEAL ET AL.
25. Inaba K, Masui S, Iida H, Vavassori S, Sitia R, and Suzuki
M. Crystal structures of human Ero1a reveal the mecha-
nisms of regulated and targeted oxidation of PDI. EMBO J
29: 3330–3343, 2010.
26. Kakihana T, Nagata K, and Sitia R. Peroxides and perox-
idases in the endoplasmic reticulum: integrating redox ho-
meostasis and oxidative folding. Antioxid Redox Signal 16:
763–771, 2012.
27. Kanemura S, Okumura M, Yutani K, Ramming T, Hikima
T, Appenzeller-Herzog C, Akiyama S, and Inaba K. Human
ER oxidoreductin-1a (Ero1a) undergoes dual regulation
through complementary redox interactions with protein-
disulfide isomerase. J Biol Chem 291: 23952–23964, 2016.
28. Kim S, Sideris DP, Sevier CS, and Kaiser CA. Balanced
Ero1 activation and inactivation establishes ER redox ho-
meostasis. J Cell Biol 196: 713–725, 2012.
29. Kimura T, Nishida A, Ohara N, Yamagishi D, Horibe T,
and Kikuchi M. Functional analysis of the CXXC motif
using phage antibodies that cross-react with protein disulphide-
isomerase family proteins. Biochem J 382: 169–176, 2004.
30. Kulp MS, Frickel E-M, Ellgaard L, and Weissman JS. Do-
main architecture of protein-disulfide isomerase facilitates its
dual role as an oxidase and an isomerase in Ero1p-mediated
disulfide formation. J Biol Chem 281: 876–884, 2006.
31. LaMantia ML and Lennarz WJ. The essential function of
yeast protein disulfide isomerase does not reside in its
isomerase activity. Cell 74: 899–908, 1993.
32. Lappi A-K and Ruddock LW. Reexamination of the role of
interplay between glutathione and protein disulfide isom-
erase. J Mol Biol 409: 238–249, 2011.
33. Llopis J, McCaffery JM, Miyawaki A, Farquhar MG, and
Tsien RY. Measurement of cytosolic, mitochondrial, and
Golgi pH in single living cells with green fluorescent pro-
teins. Proc Natl Acad Sci U S A 95: 6803–6808, 1998.
34. Masui S, Vavassori S, Fagioli C, Sitia R, and Inaba K.
Molecular bases of cyclic and specific disulfide interchange
between human ERO1alpha protein and protein-disulfide
isomerase (PDI). J Biol Chem 286: 16261–16271, 2011.
35. Montero D, Tachibana C, Rahr Winther J, and Appenzeller-
Herzog C. Intracellular glutathione pools are heteroge-
neously concentrated. Redox Biol 1: 508–513, 2013.
36. Nguyen VD, Saaranen MJ, Karala A-R, Lappi A-K, Wang
L, Raykhel IB, Alanen HI, Salo KEH, Wang C-C, and
Ruddock LW. Two endoplasmic reticulum PDI peroxidases
increase the efficiency of the use of peroxide during dis-
ulfide bond formation. J Mol Biol 406: 503–515, 2011.
37. Niu Y, Zhang L, Yu J, Wang C-C, and Wang L. Novel roles
of the non-catalytic elements of yeast protein-disulfide
isomerase in its interplay with endoplasmic reticulum oxi-
doreductin 1. J Biol Chem 291: 8283–8294, 2016.
38. Nørgaard P, Westphal V, Tachibana C, Alsøe L, Holst B,
and Winther JR. Functional differences in yeast protein
disulfide isomerases. J Cell Biol 152: 553–562, 2001.
39. Paroutis P, Touret N, and Grinstein S. The pH of the se-
cretory pathway: measurement, determinants, and regula-
tion. Physiology 19: 207–215, 2004.
40. Payne T, Finnis C, Evans LR, Mead DJ, Avery S V, Archer
DB, and Sleep D. Modulation of chaperone gene expression
in mutagenized Saccharomyces cerevisiae strains devel-
oped for recombinant human albumin production results in
increased production of multiple heterologous proteins.
Appl Environ Microbiol 74: 7759–7766, 2008.
41. Pollard MG, Travers KJ, and Weissman JS. Ero1p: a novel
and ubiquitous protein with an essential role in oxidative
protein folding in the endoplasmic reticulum. Mol Cell 1:
171–182, 1998.
42. Ramming T and Appenzeller-Herzog C. The physiological
functions of mammalian endoplasmic oxidoreductin 1: on
disulfides and more. Antioxid Redox Signal 16: 1109–1118,
2012.
43. Ramming T, Okumura M, Kanemura S, Baday S, Birk J,
Moes S, Spiess M, Jeno¨ P, Berne`che S, Inaba K, and
Appenzeller-Herzog C. A PDI-catalyzed thiol-disulfide switch
regulates the production of hydrogen peroxide by human
Ero1. Free Radic Biol Med 83: 361–372, 2015.
44. Robinson AS, Hines V, and Wittrup KD. Protein disulfide
isomerase overexpression increases secretion of foreign
proteins in Saccharomyces cerevisiae. Biotechnology 12:
381–384, 1994.
45. de Ruijter JC, Koskela E V, and Frey AD. Enhancing an-
tibody folding and secretion by tailoring the Sacchar-
omyces cerevisiae endoplasmic reticulum. Microb Cell
Fact 15: 87, 2016.
46. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V,
Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S,
Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri
K, Tomancak P, and Cardona A. Fiji: an open-source
platform for biological-image analysis. Nat Methods 9:
676–682, 2012.
47. Schultz LD, Markus HZ, Hofmann KJ, Montgomery DL,
Dunwiddie C, Kniskern PJ, Freedman RB, Ellis RW, and
Tuite MF. Using molecular genetics to improve the pro-
duction of recombinant proteins by the yeast Sacchar-
omyces cerevisiae. Ann N Y Acad Sci 721: 148–157, 1994.
48. Schwaller M, Wilkinson B, and Gilbert HF. Reduction-
reoxidation cycles contribute to catalysis of disulfide
isomerization by protein-disulfide isomerase. J Biol Chem
278: 7154–7159, 2003.
49. Sevier CS, Qu H, Heldman N, Gross E, Fass D, and Kaiser
CA. Modulation of cellular disulfide-bond formation and
the ER redox environment by feedback regulation of Ero1.
Cell 129: 333–344, 2007.
50. Shepherd C, Oka OB V, and Bulleid NJ. Inactivation of
mammalian Ero1a is catalysed by specific protein disulfide-
isomerases. Biochem J 461: 107–113, 2014.
51. Smeekens JM, Xiao H, and Wu R. Global analysis of se-
creted proteins and glycoproteins in Saccharomyces cere-
visiae. J Proteome Res 16: 1039–1049, 2017.
52. Tachibana C and Stevens TH. The yeast EUG1 gene en-
codes an endoplasmic reticulum protein that is functionally
related to protein disulfide isomerase. Mol Cell Biol 12:
4601–4611, 1992.
53. Tavender TJ, Springate JJ, and Bulleid NJ. Recycling of
peroxiredoxin IV provides a novel pathway for disulphide
formation in the endoplasmic reticulum. EMBO J 29:
4185–4197, 2010.
54. Tu BP, Ho-Schleyer SC, Travers KJ, and Weissman JS.
Biochemical basis of oxidative protein folding in the en-
doplasmic reticulum. Science 290: 1571–1574, 2000.
55. Tu BP and Weissman JS. The FAD- and O2-dependent
reaction cycle of Ero1-mediated oxidative protein fold-
ing in the endoplasmic reticulum. Mol Cell 10: 983–994,
2002.
56. Tu BP and Weissman JS. Oxidative protein folding in eu-
karyotes: mechanisms and consequences. J Cell Biol 164:
341–346, 2004.
57. Vitu E, Kim S, Sevier CS, Lutzky O, Heldman N, Bentzur
M, Unger T, Yona M, Kaiser CA, and Fass D. Oxidative
YEAST OXIDATIVE PROTEIN FOLDING PATHWAY 13
activity of yeast Ero1p on protein disulfide isomerase and
related oxidoreductases of the endoplasmic reticulum. J
Biol Chem 285: 18155–18165, 2010.
58. Wang L, Li S, Sidhu A, Zhu L, Liang Y, Freedman RB, and
Wang C. Reconstitution of human Ero1-Lalpha/protein-
disulfide isomerase oxidative folding pathway in vitro.
Position-dependent differences in role between the a and a¢
domains of protein-disulfide isomerase. J Biol Chem 284:
199–206, 2009.
59. Wang L, Zhang L, Niu Y, Sitia R, and Wang C. Glu-
tathione peroxidase 7 utilizes hydrogen peroxide generated
by Ero1a to promote oxidative protein folding. Antioxid
Redox Signal 20: 545–556, 2014.
60. Wang X, Li S, Wang H, Shui W, and Hu J. Quantitative
proteomics reveal proteins enriched in tubular endoplasmic
reticulum of Saccharomyces cerevisiae. Elife 6: e23816,
2017.
61. Wentz AE and Shusta EV. A Novel high-throughput screen
reveals yeast genes that increase secretion of heterologous
proteins. Appl Environ Microbiol 73: 1189–1198, 2007.
62. WestM, Zurek N, Hoenger A, and Voeltz GK. A 3D analysis
of yeast ER structure reveals how ER domains are organized
by membrane curvature. J Cell Biol 193: 333–346, 2011.
63. Wiederhold E, Veenhoff LM, Poolman B, and Slotboom
DJ. Proteomics of Saccharomyces cerevisiae organelles.
Mol Cell Proteomics 9: 431–445, 2010.
64. Yen K, Gitsham P, Wishart J, Oliver SG, and Zhang N. An
improved tetO promoter replacement system for regulating
the expression of yeast genes. Yeast 20: 1255–1262, 2003.
65. Young CL and Robinson AS. Protein folding and secretion:
mechanistic insights advancing recombinant protein pro-
duction in S. cerevisiae. Curr Opin Biotechnol 30: 168–
177, 2014.
66. Zhang L, Niu Y, Zhu L, Fang J, Wang X, Wang L, and
Wang C. Different interaction modes for protein-disulfide
isomerase (PDI) as an efficient regulator and a specific
substrate of endoplasmic reticulum oxidoreductin-1a
(Ero1a). J Biol Chem 289: 31188–31199, 2014.
67. Zito E, Melo EP, Yang Y, Wahlander A˚, Neubert TA, and Ron
D. Oxidative protein folding by an endoplasmic reticulum-
localized peroxiredoxin. Mol Cell 40: 787–797, 2010.
Address correspondence to:
















Date of first submission to ARS Central, July 31, 2018; date
of final revised submission, March 14, 2019; date of accep-










ERO1¼ endoplasmic reticulum oxidase 1
Ero1p¼ purified yeast ERO1









Ni-NTA¼Ni2+ loaded nitrilotriacetic acid modified
sepharose
O2¼molecular oxygen
OPF¼ oxidative protein folding
PDI¼ protein disulfide isomerase
Pdi1p¼ purified yeast PDI
PEG¼ polyethylene glycol
rdRNase A¼ reduced and denatured ribonuclease A
RMSD¼ root-mean-squared-deviation
RNase A¼ ribonuclease A
scFv¼ single chain variable fragment
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